Cellectar Biosciences Inc (CLRB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cellectar Biosciences Inc (CLRB) has a cash flow conversion efficiency ratio of -0.438x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.34 Million) by net assets ($9.92 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Cellectar Biosciences Inc to measure how many days the company can operate on defensive assets alone.
Cellectar Biosciences Inc - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how Cellectar Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Cellectar Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cellectar Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CWG Holdings Bhd
KLSE:9423
|
0.098x |
|
Auriginal Mining Corp.
V:AUME
|
-0.158x |
|
Bengal Energy Ltd
TO:BNG
|
-0.004x |
|
SHEARWATER GRP PLC LS-10
F:DTW1
|
N/A |
|
RECYCLICO BATTERY METALS
F:ID4
|
-0.015x |
|
Check-Cap Ltd.
NASDAQ:MBAI
|
N/A |
|
Vaishali Pharma Limited
NSE:VAISHALI
|
0.030x |
|
Mobio Technologies Inc
V:MBO
|
-0.288x |
Annual Cash Flow Conversion Efficiency for Cellectar Biosciences Inc (2004–2025)
The table below shows the annual cash flow conversion efficiency of Cellectar Biosciences Inc from 2004 to 2025. For the full company profile with market capitalisation and key ratios, see Cellectar Biosciences Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $9.92 Million | $-23.12 Million | -2.331x | +29.98% |
| 2024-12-31 | $14.29 Million | $-47.58 Million | -3.329x | -241.64% |
| 2023-12-31 | $-13.78 Million | $-32.38 Million | 2.350x | +188.84% |
| 2022-12-31 | $9.54 Million | $-25.22 Million | -2.645x | -287.30% |
| 2021-12-31 | $33.05 Million | $-22.57 Million | -0.683x | -168.60% |
| 2020-12-31 | $54.79 Million | $-13.93 Million | -0.254x | +80.30% |
| 2019-12-31 | $9.06 Million | $-11.69 Million | -1.291x | -49.60% |
| 2018-12-31 | $13.26 Million | $-11.44 Million | -0.863x | +15.80% |
| 2017-12-31 | $10.75 Million | $-11.02 Million | -1.025x | -67.52% |
| 2016-12-31 | $13.54 Million | $-8.28 Million | -0.612x | +87.71% |
| 2015-12-31 | $1.65 Million | $-8.21 Million | -4.978x | -505.11% |
| 2014-12-31 | $10.75 Million | $-8.84 Million | -0.823x | +84.73% |
| 2013-12-31 | $1.70 Million | $-9.15 Million | -5.387x | -730.95% |
| 2012-12-31 | $10.16 Million | $-6.59 Million | -0.648x | -2.95% |
| 2011-12-31 | $9.48 Million | $-5.97 Million | -0.630x | +90.26% |
| 2010-12-31 | $1.21 Million | $-7.80 Million | -6.468x | -1738.29% |
| 2009-12-31 | $-26.90 Million | $-10.62 Million | 0.395x | -87.28% |
| 2008-12-31 | $-5.58 Million | $-17.33 Million | 3.104x | +35.27% |
| 2007-12-31 | $-5.87 Million | $-13.47 Million | 2.294x | +476.26% |
| 2006-12-31 | $10.61 Million | $-6.47 Million | -0.610x | -20.00% |
| 2005-12-31 | $4.72 Million | $-2.40 Million | -0.508x | -667.81% |
| 2004-12-31 | $-4.35 Million | $-389.18K | 0.089x | -- |
About Cellectar Biosciences Inc
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with re… Read more